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Background: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting
remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical
adoption.
Objective: Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expres-
sion assay versus standard clinical parameters for discriminating Grade Group (GG) 2 PCa from GG1 PCa and
benign disease on initial biopsy.
Design, setting, and participants: Atwo-phaseadaptiveclinicalutilitystudy(NCT03031418)comparingEPI resultswith
biopsy outcomes in men, with age50 yr and prostate-specific antigen (PSA) 2–10 ng/ml, scheduled for initial prostate
biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was
developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain.
Outcome measurements and statistical analysis: Performance evaluation of the EPI test in patients enrolled in
phase I and publication of a consensus CarePath for phase II.
Results and limitations: In a total of 503 patients, with median age of 64 yr, median PSA 5.4 ng/ml, 14% African
American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15%  GG3), EPI was superior to an
optimizedmodel of standard clinical parameterswith an area under the curve (AUC) 0.70 versus 0.62, respectively,
comparable with previously published results (n = 519 patients, EPI AUC 0.71). Validated cut-point 15.6 would
avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and
missing 7% of GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total
biopsies, with NPV 89% andmissing 11% ofGG2 PCa. The clinical investigators reached consensus recommending
use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately.
Conclusions: EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully
validated in over 1000 patients across two prospective validation trials to stratify risk of GG2 from GG1 cancer
and benign disease. The test improves identification of patients with higher grade disease and would reduce the
total number of unnecessary biopsies.
Patient summary: It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial
biopsywith prostate-specific antigen 2–10 ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore)
test can predict GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and
standard clinical data.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
There are over a million prostate needle biopsies performed
in the USA including repeat biopsies every year, mostly as a
direct result of fluctuating or increasing levels of prostate-
specific antigen (PSA) [1]. Unfortunately, the low specificity
of PSA for prostate cancer (PCa) has led to an increase in
either benign unnecessary biopsies or the diagnosis of
clinically indolent tumors, which subject approximately
50% of men to some form of (over) treatment including
surgery, radiation, or additional biopsies as part of an active
surveillance program [1–5]. Furthermore, the biopsy
procedure is not completely benign, with an increasing
incidence of infections (3–5%) and the potential for serious
complications requiring hospitalization [6].
In 2012, the United States Preventive Services Task Force
(USPSTF) recommended against PSA screening [7]; howev-
er, to avoid missing clinically significant PCa, they produced
an updated draft recommendation in 2017 to promote age-
specific shared-decision PSA testing for men aged 55–69 yr
(https://screeningforprostatecancer.org). The emphasis on
“smart screening” has produced a variety of PSA-derived
blood tests (eg, 4Kscore, phi) and post-digital rectal exam
(DRE) urine-based gene assays (eg, MiProstate [MiPS],
SelectMDx). However, these tests have been developed in
cohorts largely outside the PSA 2–10 ng/ml grey zone
population of biopsy-naïve patients, and for some requiring
inclusion of PSA levels and other clinical standard of care
variables in their test algorithm (eg, 4Kscore, MiPS,
SelectMDx) to generate respective risk scores [8–13].
We have previously published on the development of a
urine exosome gene expression test, ExoDx Prostate
(IntelliScore) (EPI), which utilizes exosomal RNA expression
levels of three genes to predict the likelihood of having
high-grade PCa (HGPCa) of Grade Group (GG) 2 or greater
[14]. To our knowledge, EPI is the only test for this
indication, with the exception of multiparametric magnetic
resonance imaging (mpMRI) that does not incorporate PSA
or a PSA derivative in the test algorithm. As such, EPI is a
“standalone” test that does not rely on any other parameters
to calculate the score compared with the exosomal RNA
markers measured in the urine sample. This allows
clinicians to use the test result in conjunction with other
clinical variables, including clinical nomograms, mpMRI, or
standard of care risk calculators (RCs). The EPI test was
previously validated in 519 men from 22 community
practice and academic urology clinic sites in the USA, all
in the intended use population of 50 yr or older with PSA
values 2–10 ng/ml presenting for their initial biopsy
[14,15]. The validation study demonstrated good assay
performance with a pre-determined cut-point (15.6)
yielding a negative predictive value (NPV) >90%, and a
sensitivity of 92%, with 27% of patients having an EPI score
below the cut-point [14]. Using an alternative cut-point of
20, the assay missed 6% of GG3 PCas and would have
potentially avoided 37% of biopsies.
To further assess the performance of the EPI test in the
intended use population, we initiated a two-phase, prospec-
tive adaptive decision impact trial (NCT03031418), with
phaseIconstitutingasecondvalidationcohortof500patients
leading to a cut-point recommendation and agreement
among the principal investigators on a clinical implementa-
tion plan (ie, a “CarePath”). The CarePath will be used in a
subsequent phase II 500-patient cohort consisting of men
aged50 yrwith a PSA 2–10 ng/ml forwhich the decision to
perform an initial biopsy is uncertain. We now report on the
performanceofEPI in cohort1 and theoutcomeof the clinical
investigator CarePath consensus. Outcome of the second
utility phase of the study will be reported separately.
2. Patients and methods
2.1. Study setting and population
We report on the second validation of a prospective, two-cohort, adaptive
clinical implementation and utility study of the EPI urine exosome gene
expression assay comparing EPI results with biopsy outcomes. Eligible
participants had not been diagnosed with PCa, were aged 50 yr with a
PSA 2–10 ng/ml, and scheduled for their initial prostate needle biopsy.
After completion of cohort 1, a clinical implementation document (ie,
CarePath) was developed for utilizing the EPI score in a second phase
patient cohort, where the biopsy decision is uncertain.
2.2. Study design
This report constitutes the planned prospective phase I analysis
correlating the EPI test result with biopsy outcomes on 500 eligible
patients, cohort 1, (ie, age of 50 yr, PSA 2–10 ng/ml, and scheduled for
initial biopsy) in the multisite, expanded validation adaptive utility trial
(NCT03031418). At the time of this phase I analysis, 14 clinical sites in the
USA participated from May 2016 to August 2017 (Supplementary
Table 1). All cohort 1 patients underwent an EPI test independent to the
prostate needle biopsy outcome. All personnel involved in operational
activities of the validation studies including execution of the EPI test
were blinded to the outcome.We have adopted the more patient-centric
prognostic GGs developed at Johns Hopkins Hospital and endorsed by
the International Society of Urological Pathology: GS2-6 = GG1, GS 3
+ 4 = GG2, GS4 + 3 = GG3, GS8 = GG4 and GS9-10 = GG5 [15–17]. Clinical
features (ie, PSA, age, race, DRE, and family history) available at the time
of enrollment were obtained. Men with a history of a prior biopsy,
invasive treatment for benign prostatic disease, or taking medications
that influence serum PSA levels within 6 mo were excluded. Men with
active prostatitis on antibiotics were also excluded. Pathologic exami-
nation of biopsies, blinded to EPI test result, was performed by urologic
pathologists at each study site.
The study protocol was approved by local institutional review boards
(IRBs); all participants provided written informed consent and were not
compensated for participating. The protocol and statistical analysis plan
were agreed upon by all investigators prior to patient enrollment and
study data collection. Analyses of test results with biopsy outcomes
including performance of the previously validated and alternative cut-
points were evaluated by the principal investigators and pre-identified
external content experts. A consensus opinion, CarePath, was developed




EPI is a non-DRE urine-based liquid biopsy test indicated for men aged
50 yr with a PSA 2–10 ng/ml being considered for an initial prostate
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needle biopsy. All sites received a urine collection vessel and shipping
kits. First-catch 15–20 ml urine samples were collected from all enrolled
patients and stored at 4 C for up to 5 d prior to shipping to a central
laboratory (ExosomeDiagnostics, Inc,Waltham,MA) for EPI test analysis.
Description of methods used in exosome isolation, RNA extraction, and
reverse transcriptase polymerase chain reaction have been analytically
validated and previously published [13,14]. Briefly, the test result is
calculated based on the relative gene expression of three genes, without
inclusion of other clinical parameters, and provides a risk score (scale 0–
100) that predicts the presence of HGPCa (GG2). Men with a score
15.6 (or 20) are at increased risk for having HGPCa on a subsequent
biopsy.
2.4. Statistical methods
One of the primary objectives of this scheduled phase I analysis was to
perform a second validation of the EPI test for predictingHGPCa on initial
biopsy for men with a PSA 2–10 ng/ml in a prospective, multisite trial.
Besides EPI alone, logistic regression models from McKiernan et al. [14]
with a standard of care model (SOCm, including PSA level, age, race, and
family history), with (SOCm + EPI) and without (SOCm) the EPI score,
were used to predict the biopsy result for HGPCa (ie, biopsy negative and
GG1 vs GG2). We also employed both the Prostate Cancer Prevention
Trial (PCPT 2.0) and European Randomized Study of Screening for
Prostate Cancer (ERSPC) RCs to further characterize the investigated
cohort for risk of PCa using existing standard of care clinical parameters
[18,19]. As prostate volume is not routinely provided in the enrolled
patient populations, we used the ERSPC RC which incorporates PSA and
DRE for men without previous biopsy [20]. Receiver operating
characteristics (ROCs) for all models assessed clinical performance.
Missing DRE results were imputed as nonsuspicious.
Cohort 1 second validation results were comparedwith performance
of the previously published validation cohort utilizing area under the
curve (AUC) of the ROC, assessment of the cut-point sensitivity,
specificity, negative predictive value (NPV), and positive predictive
value (PPV). Analyses were performed as outlined above. Where
applicable, confidence intervals were calculated using Clopper-Pearson
method. DeLong's test was applied to assess the significance of AUC
differences between analyses. The clinical value of the EPI test was
assessed with a decision curve analysis to evaluate the net health benefit
of the urine exosome gene expression assay for predicting HGPCa.
2.5. Consensus conference
After completion of phase I of the trial, a panel of clinicians and risk
modeling experts (J.M., M.J.D., E.M., A.P., B.C., G.B., N.S., G.A., R.E., I.T. and P.
C.) convened at a Consensus Conference to review the performance of the
EPI test in cohort 1 and to compare the results with previous validation
study results using both the validated and alternative cut-points of
15.6 and 20, respectively. A consensus recommendationwas reached and
documented in an EPI clinical CarePath, which was submitted for IRB
approval for use in the decision impact phase II of the trial.
3. Results
3.1. Study population
Of the 532 patients enrolled in cohort 1, 503were evaluable;
two patients were removed for PSA >10 ng/ml, one patient
was aged <50 yr, two had urine volumes <15 ml, and
26 patients (5%) had gene expression and/or internal quality
control levels outside assay acceptance limits. Four sites
enrolled >70% of the patients representing three commu-
nity practice centers (Urology Center of Englewood New
Jersey, USA; Delaware Valley Urology, New Jersey, USA; and
Associated Urologists of North Carolina, USA) and one large
academic medical center (Johns Hopkins University, Balti-
more, MD, USA; see Supplementary materials for complete
trial site list and patient enrollment). The participating
clinical sites between the original and current validation
studies were comparable with respect to geography and
general patient characteristics. Although 65.5% of patients
in the original validation study and 57.3% of patients in the
present cohort 1 were enrolled at the same urology centers,
this trial represents a second, independent prospective
study. The present study was performed 2 yr after the
original study, following separate collection protocols and
was not an extension of the first. In the original validation
study, 6% of patients were enrolled at academic sites in
contrast to 22% in the present study. In both studies, the
remaining patients were enrolled at local community
practices, reflecting real-world experience in the USA.
The median age was 64 yr, with a median PSA of 5.4 ng/ml;
14% of patients self-reported a positive family history of PCa
and 70% identified as Caucasianwith 14% African American,
4% Asian, 5% Hispanic, and 7% not available or other. DRE
was nonsuspicious in 75%, suspicious in 12.5%, and not
available in 12.5%. MRI-guided biopsies were performed in a
minority (9.3%) of patients in the current study. Complete
demographic and clinical characteristics of final evaluable
cohort are summarized in Table 1.
Table 1 – Demographic and clinical characteristics of cohort 1
Registration cohort
Total 503
Age median, IQR 64 (59–69)
PSA median, IQR 5.4 (4.4–6.7)





African American 71 (14.1)
Asian/Pacific Islander 18 (3.6)
Caucasian 350 (69.6)
Hispanic 25 (5)







Grade Group, n (%)
Benign 234 (46.5)
GG 1 (ISUP1, GS3 + 3) 111 (22.1)
GG 2 (ISUP2, GS3 + 4) 86 (17.1)
GG 3 (ISUP3, GS4 + 3) 26 (5.2)
GG 4 (ISUP4, all GS8) 26 (5.2)
GG 5 (ISUP5, >GS8) 20 (4)
GG 3 (ISUP3, GS4 + 3) 72 (14.3)
DRE = digital rectal exam; GG = Grade Group; GS = Gleason score;
IQR = interquartile range; ISUP = International Society of Urological
Pathology; PSA = prostate-specific antigen.
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3.2. Biopsy outcome (GG classification)
Of the 503 patients, 88% underwent a 12-core, transrectal
ultrasound-guided prostate needle biopsy with diagnosis
performed at individual site-designated pathology practices.
There was no central pathology diagnosis rendered during
the trial. The total positive biopsy ratewas 53%: 22%GG1 and
31% GG2 (Table 1). Although PSA and age were quite
comparable between the previous validation study and the
current cohort (year 2014 vs 2016), therewas a 5% increase in
the positive biopsy rate (48% to 53%) and a 3% increase in the
diagnosis ofGG2 PCa (28% to 31%). Of possible significance,
the GG3 was slightly increased (12% vs 14%).
3.3. EPI as a predictor of GG2 PCa
On comparing the performance of the EPI test with
alternative models, the EPI test was superior to SOCm,
ERSPC-RC, PCPT-RC, and PSA alone for predictingGG2 PCa
in both the second and first validation cohort (Fig. 1A and
1B; Table 2). The DeLong test comparing differences
between AUC curves further demonstrated good indepen-
dent performance of the EPI test.
By applying an EPI cut-point of 15.6 for predicting GG2
PCa, the EPI test demonstrated an NPV of 89% with a
sensitivity of 93% and would have avoided 20% of all
[(Fig._1)TD$FIG]
Fig. 1 – Area under receiver operating characteristic (AUC) curves are shown to compare performances of EPI in (A) the current cohort (n = 503) and (B)
the previous validation cohort (n = 519) with and without the SOCm, PCPT-RC, ERSPC-RC, and PSA alone. The corresponding net benefit analysis for the
two cohorts is shown (C) for current validation cohort and (D) for previous validation cohort.
EPI = ExoDx Prostate (IntelliScore); ERSPC-RC = European Randomized Study of Screening for Prostate Cancer risk calculator; PCPT-RC = Prostate Cancer
Prevention Trial risk calculator; PSA = prostate-specific antigen; SOCm = standard of care model.
Table 2 – Performance comparison (AUC, 95% CI) of the EPI test to
alternative models and DeLong test for significance
Test/model Current cohort (n = 503) Original validation cohort
(n = 519)
AUC (95% CI) p value AUC (95% CI) p value
EPI 0.70 (0.65–0.75) – 0.71 (0.66–0.76)
EPI + SOCm 0.71 (0.66–0.76) 0.1457 0.73 (0.68–0.77) 0.3629
SOCm 0.62 (0.57–0.67) 0.0140 0.63 (0.58–0.68) 0.0027
PCPT-RC 0.63 (0.58–0.68) 0.0209 0.62 (0.57–0.67) 0.0032
ERSPC-RC 0.59 (0.54–0.64) 0.0014 0.58 (0.52–0.63) <0.0001
PSA 0.58 (0.53–0.63) 0.0005 0.55 (0.49–0.60) <0.0001
AUC = area under curve; CI = confidence interval; EPI = ExoDx Prostate
(IntelliScore); ERSPC-RC = European Randomized Study of Screening for
Prostate Cancer risk calculator; PCPT-RC = Prostate Cancer Prevention Trial
risk calculator; PSA = prostate-specific antigen; SOCm = standard of care
model.
EPI has a significantly higher AUC than all alternative models, except the
combined model of EPI + SOCm. AUCs from the cohort of n = 503 patients
are nearly identical to the original validation cohort of n = 519.
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biopsies (n = 503) or 26% of unnecessary, negative/GG1
biopsies (n = 345; Table 3). The assay missed 11 of 158 (7%)
GG2 cancers of which seven were GG3. Of note, the
15.6 cut point in the original validation cohort produced a
similar NPV of 91% and sensitivity of 92%, while avoiding
27% of biopsies, and 12 of 148 (8%) GG2 cancers were
missed of which three were GG3.
We also investigated the clinical value of the EPI test
relative to alternative models using a decision curve
analysis (Fig. 1C and 1D). EPI's performance was superior
(highest net benefit) to all models tested, including SOCm,
PCPT-RC, ERSPC-RC, and PSA. The distribution of biopsy
results from patients with different EPI scores is also shown
in a waterfall plot from the current validation cohort,
illustrating the distribution of HGPCa above and below the
cut-point (Fig. 2).
Further, we previously reported that the EPI test
performed equally well with an alternative cut-point of
20. In this second validation cohort, an EPI score of
20 produced an NPV of 89% with a sensitivity of 89% and
would avoid 31% of all biopsies and 40% of negative/GG1
biopsies (Table 4). The assay missed 17 of 158 (11%) GG2
cancers of which nine were GG3. For completeness, we
have also included a table of results across a range of
different cut-points (Supplementary Table 2).
A direct comparison of cut-point performances relative
to available alternatives was performed at a 90% fixed
sensitivity analysis of EPI against PSA and standard of care
RCs (Table 5).
3.4. Consensus CarePath
As outlined in the study protocol, a panel of principal
investigators and pre-identified external content experts
convened to reach consensus on CarePath for EPI test
implementation in phase II of the current adaptive utility
trial. The panel first confirmed that the demographics and
phenotypic characteristics of the patients enrolled in the
previous and current validation studies were similar. The
panel took note of the observed 5% increase in the positive
biopsy rate and discussed that this could be a reflection of
the 2012 USPSTF reduced PSA screening recommendations
but that this difference did not appear to impact perfor-
mance of the EPI test. The panel agreed that the primary
Table 3 – Performance of the EPI test with a cut-point of 15.6 in the second validation cohort 1
EPI  cut-point EPI < cut-point Total Performance, % (95% CI)
Biopsy Positive/  GG2 147 11 158 Sensitivity, 93 (87.9–96.5)
Biopsy Negative/GG1 255 90 345 Specificity, 26.1 (21.5–31.1)
Total 402 101 503 PPV, 36.6 (31.8–41.5)
NPV, 89.1 (81.3–94.4)
Prevalence 31.4% Predicted negative 20.1%
CI = confidence interval; EPI = ExoDx Prostate (IntelliScore); GG = Grade Group; NPV = negative predictive value; PPV = positive predictive value.
[(Fig._2)TD$FIG]
Fig. 2 – Waterfall plot of the EPI scores in relation to prostate biopsy outcomes across cohort 1 (n = 503). EPI scores are shown on Y-axis and the Grade
Group biopsy results illustrated in blue, yellow, or red.
EPI = ExoDx Prostate (IntelliScore); GG = Grade Group.
Table 4 – Performance of the EPI test with a cut-point of 20 in the second validation cohort 1
EPI  cut-point EPI < cut-point Total Performance, % (95% CI)
Biopsy Positive/  GG2 141 17 158 Sensitivity, 89.2 (83.3–93.6)
Biopsy Negative/GG1 207 138 345 Specificity, 40 (34.8–45.4)
Total 348 155 503 PPV, 40.5 (35.3–45.9)
NPV, 89 (83.0–93.5)
Prevalence 31.4% Predicted negative 30.8%
CI = confidence interval; EPI = ExoDx Prostate (IntelliScore); GG = Grade Group; NPV = negative predictive value; PPV = positive predictive value.
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endpoint of validating EPI performance was met and that
the EPI test was superior to the standard of care for
predicting HGPCa in the intended use population.
After a comprehensive review of the phase I outcome and
the previously published validation study, the panel unani-
mously recommended to use the 15.6 cut point formen aged
50 yr, with a PSA of 2–10 ng/ml presenting for their initial
biopsy in the second phase of the study. The panel
determinedthatwhile thealternative cut-pointof20avoided
additional biopsies, it also produced more false-negatives,
and to reduce risk, there was uniform agreement to proceed
with themore conservative cut-point inphase II of the study,
where biopsy decision is uncertain. There was uniform
agreement that the EPI test would not be used in a “clinical
vacuum” and since the EPI score does not incorporate
standard clinical parameters, the real-world experience
would likely yield fewer missed GG2 biopsies. The EPI score
is not a dichotomous variable that leads to an absolute biopsy
decisionbut rathera risk stratification tool (highvs lowriskof
HGPCa) that can be added to the shared decision-making
process between a patient and his urologist regarding
appropriate next steps. A CarePath document was subse-
quently authored by the panel and submitted for approval by
the respective IRBs (Supplementary materials). Upon ap-
proval, theCarePathwasprovided to theclinical investigators
enrolling patients in the decision impact phase II of the trial.
4. Discussion
PCa remains themost commonnondermatologicmalignancy
among men in the USA and Europe. It is a major health
concern, especially in developed countries with a greater
proportion of elderly men in the general population
[21,22]. The use of PSA for opportunistic and general
screening has produced an overall reduction in PCamortality
but resulted in a substantial increase in unnecessary biopsies
alongwith the detection of clinically low-risk asymptomatic
cancers [23]. Furthermore, more than a million biopsies
performed every year in the USA alone has produced an
increase in infectious complications; according to some
studies, the 30-d hospitalization rate rose from 1.0% in
1996 to 4.1% in 2005 and 75% were for sepsis [24]. Although
the published frequency of these complications is quite
variable (0–6.5%) [6], the number of men requiring medical
intervention continues to rise, especially for those with
fluoroquinolone-resistant intestinal flora [25].
The decreased PSA screening recommendation by the
2012 USPSTF has reduced the overall number of biopsies
performed and has also reportedly increased the positive
biopsy rate; however, nationally representative studies are
lacking [26–29]. Furthermore, there has been an observed
increase in the diagnosis of more clinically significant
disease, suggesting that potentially important cancers are
not being diagnosed early enough. From the original (2014)
to current trial (2016), we observed a 5% increase in the
positive biopsy rate (48% to 53%) with an increase in GG3 by
2%, suggesting that such trends may have impacted the
cohort composition. The challenges associated with the use
of PSA have emphasized the need to developmore objective
measures for identifying clinically significant PCa while
continuing to reduce the sequence of over-diagnosis and
over-treatment. Such efforts have given rise to several
blood- and urine-based commercial assays, notably Prostate
Health Index (phi, Beckman Coulter, Brea, California, USA),
4Kscore (Opko, Miami, Florida, USA), PCA3 (Gen-Probe, San
Diego, CA, USA), and SelectDx (MDx Health, Herstal,
Belgium).
We have previously validated a noninvasive, urinary
three-gene expression assay, EPI, to discriminate GG2
cancer from GG1 and benign disease for men aged 50 yr,
undergoing initial biopsy with PSA levels 2–10 ng/ml
[14]. In the current trial, the EPI test underwent an
additional independent prospective validation on
503 men, and the results replicated the original study
(AUC 0.70 vs AUC 0.71, respectively) including superiority to
well-established RCs, such as PCPT-RC (AUC 0.63), ERSPC-RC
(AUC 0.58), and PSA alone (AUC0.58). The present EPI
validation study targeted the intended use population of
menwith a PSA 2–10 ng/ml at initial biopsy, where standard
of care parameters are less informative. Furthermore, EPI
alone had an AUC of 0.70, while EPI combined with the
SOCm was 0.71 (95% confidence interval: 0.66–0.76),
supporting independent performance of EPI from clinical
variables. Of note, to effectively evaluate the performance of
EPI with other available commercial assayswould, however,
require an assessment within this intended use population.
In the second validation cohort in this study (n = 503), an
EPI score <15.6 would have avoided biopsies in 101 men
(20%), or 26% unnecessary biopsies while missing 11 men
(7%) with GG2 PCa of which seven patients had GG3.
These results are comparable with the original validation
study of 8% GG2 false-negatives. Applying a cut point of
20 in this second validation cohort would potentially avoid
Table 5 – Performance comparison of EPI to alternative models at 90% fixed sensitivity in the current cohort of n = 503 patients
Method Sensitivity Specificity NPV PPV % classified negative
EPI 90 (84.1–94.1) 38.6 (33.4–43.9) 89.3 (83.1–93.7) 40.1 (35.0–45.4) 29.6 (25.7–35.7)
SOCm + EPI 90 (84.1–94.1) 33.6 (28.7–38.9) 87.9 (81.1–92.9) 38.8 (33.3–43.4) 26.2 (22.4–30.3)
SOCm 90 (84.1–94.1) 19.1 (15.1–23.7) 80.5 (70.3–88.4) 33.7 (29.2–38.5) 16.3 (13.2–19.8)
PCPT 90 (84.1–94.1) 21.4 (17.2–26.2) 82.2 (72.7–89.5) 34.4 (29.8–39.2) 17.9 (14.6–21.5)
ERSPC 90 (84.1–94.1) 18.8 (14.9–23.4) 80.2 (69.9–88.3) 33.6 (29.2–38.4) 16.1 (13.0–19.6)
PSA 90 (84.1–94.1) 19.7 (15.6–24.3) 81.0 (70.9–88.7) 33.9 (29.4–38.6) 16.7 (13.5–20.3)
EPI = ExoDx Prostate (IntelliScore); ERSPC = European Randomized Study of Screening for Prostate Cancer; NPV = negative predictive value; PPV = positive
predictive value; PCPT = Prostate Cancer Prevention Trial; PSA = prostate-specific antigen; SOCm = standard of care model.
Confidence intervals as determined by the Clopper-Pearson method are given in parentheses for each performance measure.
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31% or 40% unnecessary biopsies while missing 17 (11%)
men with GG2 of which nine (12%) had GG3.
Importantly, in the decision curve analyses, EPI when
compared with PSA and clinical-only models (ie, SOCm,
PCPT-RC, and ERSPC) demonstrated a higher net benefit
beginning at a biopsy threshold probability of 10%, which
was maintained up to a maximum of 30%. It is understood
that the determination of acceptable risk and biopsy
threshold for missing high-grade disease is based on a
shared decision-making process between the patient and
urologist. This is further complicated in the initial biopsy
setting with PSA in the 2–10 ng/ml gray zone where
patient anxiety is most likely increased. As EPI perfor-
mance is independent of clinical variables, it may be
combined with other parameters such as clinical prefer-
ence and comorbidities for developing a more personal-
ized risk assignment.
Amajor strength of the present study is that it represents
an additional prospective validation of the EPI test on a
clinically similar cohort of patients as the original validation
study (ie, men aged50 yr, undergoing initial biopsy with a
PSA 2–10 ng/ml). There are, however, a few limitations
including absence of a mpMRI feature for the majority
(>90%) of enrolled patients. To address this point, additional
clinical trials are currently in progress to include mpMRI
outcomes correlated with the EPI score. Other limitations
include the absence of a free PSA and prostate volume,
neither of which are routinely performed for themajority of
contemporary patients in the USA. Finally, we did not have a
central pathology review on all diagnostic biopsies;
however, our main goal was to evaluate EPI performance
based on routine laboratory practices.
We convened a multidisciplinary panel of experts
including principal investigators, external non-trial urolo-
gists, and computational biologists with experience in
clinical risk assessment models to review results of the
independent second and previous validation studies.
Utilizing a prepared dossier of EPI performance character-
istics, the consensus group confirmed the accuracy of the
EPI test for discriminating HGPCa of GG2 from benign and
GG1 biopsies in men aged 50 yr, with a PSA 2–10 ng/ml
presenting for their initial biopsy. After a comprehensive
assessment of cut-point performance, specifically the false-
negative rate, the consensus group recommended that a
cut-point of 15.6 be utilized for the intended use population
in cohort 2 utility trial participants. A document was
provided to the respective IRBs for implementation and
guidance.
5. Conclusions
In summary, the EPI test performed equally well in a second
prospective independent second validation study for
predicting HGPCa of GG2 in men presenting for their
initial biopsy with a PSA 2–10 ng/ml. In an analysis of over
1000 men from two cohorts, the EPI test was superior to
both the PCPT and ERSPC RCs for predicting clinically
significant PCa on initial biopsy. An expert consensus panel
determined that an EPI score of >15.6 be used to
discriminate patients as high-risk for GG2 PCa on their
initial biopsy. This assessment was incorporated into a
guidance document for phase II patients in the decision
impact trial.
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